{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T14:00:59Z","timestamp":1793973659003,"version":"4.8.0"},"reference-count":27,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T00:00:00Z","timestamp":1574294400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Key R&D Program of China","award":["2016YFC0905500 and 2016YFC0905503"],"award-info":[{"award-number":["2016YFC0905500 and 2016YFC0905503"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Funds of China","doi-asserted-by":"crossref","award":["81972898, 81602005, 81702283, 81872499, and 81602011"],"award-info":[{"award-number":["81972898, 81602005, 81702283, 81872499, and 81602011"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100005063","name":"Excellent Young Talents Fund Program of Higher Education Institutions of Anhui Province","doi-asserted-by":"crossref","award":["16zxyc04"],"award-info":[{"award-number":["16zxyc04"]}],"id":[{"id":"10.13039\/501100005063","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Central Basic Scientific Research Fund for Colleges-Young Teacher Training Program of Sun Yat-sen University","award":["17ykpy81"],"award-info":[{"award-number":["17ykpy81"]}]},{"name":"Science and Technology Program of Guangdong Province","award":["2017B020227001"],"award-info":[{"award-number":["2017B020227001"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s40425-019-0808-5","type":"journal-article","created":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T11:03:17Z","timestamp":1574334197000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":167,"title":["Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition"],"prefix":"10.1136","volume":"7","author":[{"given":"Xuanye","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenfeng","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuyu","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoshi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqi","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxiang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunpeng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruihua","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5632-6857","authenticated-orcid":false,"given":"Shaodong","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,11,21]]},"reference":[{"key":"808_CR1","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s40425-018-0316-z","volume":"6","author":"J Gong","year":"2018","unstructured":"Gong J, Chehrazi-Raffle A, Reddi S, Salgia R. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. Journal for immunotherapy of cancer. 2018;6:8.","journal-title":"Journal for immunotherapy of cancer"},{"key":"808_CR2","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et al. Management of Immune-Related Adverse Events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2018;36:1714\u201368.","journal-title":"J Clin Oncol"},{"key":"808_CR3","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1056\/NEJMra0801644","volume":"359","author":"JL Dienstag","year":"2008","unstructured":"Dienstag JL. Hepatitis B virus infection. N Engl J Med. 2008;359:1486\u2013500.","journal-title":"N Engl J Med"},{"issue":"4","key":"808_CR4","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1001\/jamaoncol.2018.6437","volume":"5","author":"SD Ramsey","year":"2019","unstructured":"Ramsey SD, Unger JM, Baker LH, Little RF, Loomba R, Hwang JP, et al. Prevalence of Hepatitis B Virus, Hepatitis C Virus, and HIV Infection Among Patients With Newly Diagnosed Cancer From Academic and Community Oncology Practices. JAMA Oncol. 2019;5(4):497\u2013505.","journal-title":"JAMA Oncol"},{"key":"808_CR5","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1053\/j.gastro.2017.02.009","volume":"152","author":"R Loomba","year":"2017","unstructured":"Loomba R, Liang TJ. Hepatitis B Reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions. Gastroenterology. 2017;152:1297\u2013309.","journal-title":"Gastroenterology"},{"key":"808_CR6","doi-asserted-by":"crossref","unstructured":"Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology (Baltimore, Md) 2018;67:1560\u20131599.","DOI":"10.1002\/hep.29800"},{"key":"808_CR7","doi-asserted-by":"crossref","unstructured":"Lake AC. Hepatitis B reactivation in a long-term nonprogressor due to nivolumab therapy. AIDS (London, England) 2017;31:2115\u20132118.","DOI":"10.1097\/QAD.0000000000001599"},{"key":"808_CR8","doi-asserted-by":"publisher","first-page":"3103","DOI":"10.1093\/annonc\/mdx502","volume":"28","author":"AS Koksal","year":"2017","unstructured":"Koksal AS, Toka B, Eminler AT, Hacibekiroglu I, Uslan MI, Parlak E. HBV-related acute hepatitis due to immune checkpoint inhibitors in a patient with malignant melanoma. Annals of oncology : official journal of the European Society for Medical Oncology. 2017;28:3103\u20134.","journal-title":"Annals of oncology : official journal of the European Society for Medical Oncology"},{"key":"808_CR9","doi-asserted-by":"publisher","first-page":"5985131","DOI":"10.1155\/2018\/5985131","volume":"2018","author":"A Pandey","year":"2018","unstructured":"Pandey A, Ezemenari S, Liaukovich M, Richard I, Boris A. A rare case of Pembrolizumab-induced reactivation of Hepatitis B. Case reports in oncological medicine. 2018;2018:5985131.","journal-title":"Case reports in oncological medicine"},{"key":"808_CR10","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1200\/JCO.2008.18.0182","volume":"27","author":"W Yeo","year":"2009","unstructured":"Yeo W, Chan TC, Leung NW, Lam WY, Mo FK, Chu MT, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol. 2009;27:605\u201311.","journal-title":"J Clin Oncol"},{"key":"808_CR11","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1001\/jama.2014.15704","volume":"312","author":"H Huang","year":"2014","unstructured":"Huang H, Li X, Zhu J, Ye S, Zhang H, Wang W, et al. Entecavir vs lamivudine for prevention of Hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical TrialEntecavir vs lamivudine to prevent HBVEntecavir vs lamivudine to prevent HBV. JAMA. 2014;312:2521\u201330.","journal-title":"JAMA"},{"key":"808_CR12","doi-asserted-by":"crossref","unstructured":"Tio M, Rai R, Ezeoke OM, McQuade JL, Zimmer L, Khoo C, et al. Anti-PD-1\/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B\/C infection. Eur J Cancer (Oxford, England : 1990) 2018;104:137\u2013144.","DOI":"10.1016\/j.ejca.2018.09.017"},{"key":"808_CR13","doi-asserted-by":"crossref","unstructured":"El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial. Lancet (London, England) 2017;389:2492\u20132502.","DOI":"10.1016\/S0140-6736(17)31046-2"},{"key":"808_CR14","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","volume":"19","author":"AX Zhu","year":"2018","unstructured":"Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer D, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. The Lancet Oncology. 2018;19:940\u201352.","journal-title":"The Lancet Oncology"},{"key":"808_CR15","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","volume":"26","author":"ME Keir","year":"2008","unstructured":"Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677\u2013704.","journal-title":"Annu Rev Immunol"},{"key":"808_CR16","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252\u201364.","journal-title":"Nat Rev Cancer"},{"key":"808_CR17","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1111\/j.1365-2893.2009.01172.x","volume":"17","author":"T Watanabe","year":"2010","unstructured":"Watanabe T, Bertoletti A, Tanoto TA. PD-1\/PD-L1 pathway and T-cell exhaustion in chronic hepatitis virus infection. J Viral Hepat. 2010;17:453\u20138.","journal-title":"J Viral Hepat"},{"key":"808_CR18","doi-asserted-by":"crossref","unstructured":"Cho H, Kang H, Lee HH, Kim CW. Programmed cell death 1 (PD-1) and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) in viral Hepatitis. Int J Mol Sci. 2017;18.","DOI":"10.3390\/ijms18071517"},{"key":"808_CR19","doi-asserted-by":"publisher","first-page":"4215","DOI":"10.1128\/JVI.02844-06","volume":"81","author":"C Boni","year":"2007","unstructured":"Boni C, Fisicaro P, Valdatta C, Amadei B, Di Vincenzo P, Giuberti T, et al. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol. 2007;81:4215\u201325.","journal-title":"J Virol"},{"key":"808_CR20","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.molimm.2007.07.038","volume":"45","author":"G Peng","year":"2008","unstructured":"Peng G, Li S, Wu W, Tan X, Chen Y, Chen Z. PD-1 upregulation is associated with HBV-specific T cell dysfunction in chronic hepatitis B patients. Mol Immunol. 2008;45:963\u201370.","journal-title":"Mol Immunol"},{"key":"808_CR21","doi-asserted-by":"publisher","first-page":"288","DOI":"10.5009\/gnl14368","volume":"10","author":"H Cho","year":"2016","unstructured":"Cho H, Kang H, Kim CW, Kim HY, Jang JW, Yoon SK, et al. Phenotypic characteristics of PD-1 and CTLA-4 expression in symptomatic acute Hepatitis a. Gut and liver. 2016;10:288\u201394.","journal-title":"Gut and liver"},{"key":"808_CR22","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1053\/j.gastro.2013.12.036","volume":"146","author":"PA Knolle","year":"2014","unstructured":"Knolle PA, Thimme R. Hepatic immune regulation and its involvement in viral hepatitis infection. Gastroenterology. 2014;146:1193\u2013207.","journal-title":"Gastroenterology"},{"key":"808_CR23","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1172\/JCI36604","volume":"119","author":"D Franceschini","year":"2009","unstructured":"Franceschini D, Paroli M, Francavilla V, Videtta M, Morrone S, Labbadia G, et al. PD-L1 negatively regulates CD4+CD25+Foxp3+ Tregs by limiting STAT-5 phosphorylation in patients chronically infected with HCV. J Clin Invest. 2009;119:551\u201364.","journal-title":"J Clin Invest"},{"key":"808_CR24","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1182\/blood.V126.23.848.848","volume":"126","author":"T Asano","year":"2015","unstructured":"Asano T, Kishi Y, Meguri Y, Yoshioka T, Iwamoto M, Maeda Y, et al. PD-1 signaling has a critical role in maintaining regulatory T cell homeostasis; implication for Treg depletion therapy by PD-1 blockade. Blood. 2015;126:848.","journal-title":"Blood"},{"key":"808_CR25","doi-asserted-by":"publisher","first-page":"e63818","DOI":"10.1371\/journal.pone.0063818","volume":"8","author":"D Gardiner","year":"2013","unstructured":"Gardiner D, Lalezari J, Lawitz E, DiMicco M, Ghalib R, Reddy KR, et al. A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection. PLoS One. 2013;8:e63818.","journal-title":"PLoS One"},{"key":"808_CR26","doi-asserted-by":"crossref","unstructured":"Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology (Baltimore, Md) 2009;49:1503\u20131514.","DOI":"10.1002\/hep.22841"},{"key":"808_CR27","doi-asserted-by":"publisher","first-page":"iv264","DOI":"10.1093\/annonc\/mdy162","volume":"29","author":"J Haanen","year":"2018","unstructured":"Haanen J, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology : official journal of the European Society for Medical Oncology. 2018;29:iv264\u20136.","journal-title":"Annals of oncology : official journal of the European Society for Medical Oncology"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0808-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40425-019-0808-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0808-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T13:46:06Z","timestamp":1601041566000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-019-0808-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,21]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["808"],"URL":"https:\/\/doi.org\/10.1186\/s40425-019-0808-5","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,21]]},"assertion":[{"value":"23 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Sun Yat-sen University Cancer Center Institutional Review Board.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"322"}}